ATE319476T1 - Neuartige nicht pyrogene bakterienstämme und ihre verwendung - Google Patents

Neuartige nicht pyrogene bakterienstämme und ihre verwendung

Info

Publication number
ATE319476T1
ATE319476T1 AT96945937T AT96945937T ATE319476T1 AT E319476 T1 ATE319476 T1 AT E319476T1 AT 96945937 T AT96945937 T AT 96945937T AT 96945937 T AT96945937 T AT 96945937T AT E319476 T1 ATE319476 T1 AT E319476T1
Authority
AT
Austria
Prior art keywords
pyrogenic
strains
present
preparation
relates
Prior art date
Application number
AT96945937T
Other languages
English (en)
Inventor
David M Hone
Robert J Powell
Original Assignee
David M Hone
Robert J Powell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David M Hone, Robert J Powell filed Critical David M Hone
Application granted granted Critical
Publication of ATE319476T1 publication Critical patent/ATE319476T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
AT96945937T 1995-11-22 1996-11-22 Neuartige nicht pyrogene bakterienstämme und ihre verwendung ATE319476T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US747895P 1995-11-22 1995-11-22

Publications (1)

Publication Number Publication Date
ATE319476T1 true ATE319476T1 (de) 2006-03-15

Family

ID=21726420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96945937T ATE319476T1 (de) 1995-11-22 1996-11-22 Neuartige nicht pyrogene bakterienstämme und ihre verwendung

Country Status (6)

Country Link
US (2) US5997881A (de)
EP (1) EP0841941B1 (de)
AT (1) ATE319476T1 (de)
AU (1) AU2278497A (de)
DE (1) DE69635907D1 (de)
WO (1) WO1997018837A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM399594A0 (en) * 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6887483B2 (en) 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
NZ503376A (en) * 1997-09-10 2002-10-25 Vion Pharmaceuticals Inc Genetically modified Salmonella sp having a modified msbB gene useful for treating tumours
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
AU762825B2 (en) * 1998-09-11 2003-07-03 Archer-Daniels-Midland Company Bacterial strains for the production of 2-keto-L-gulonic acid
DE19844191A1 (de) * 1998-09-28 2000-03-30 Pharma Zentrale Gmbh Lipopolysaccharide aus Escherichia coli
CA2386806A1 (en) * 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Non-invasive tumor imaging by tumor-targeted bacteria
WO2001025254A2 (en) * 1999-10-04 2001-04-12 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
CZ20024224A3 (cs) 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
ATE525078T1 (de) * 2000-10-06 2011-10-15 Symbio Herborn Group Gmbh U Co Kyberdrug als autovakzine mit immunregulierenden wirkungen
WO2002040046A1 (en) * 2000-11-16 2002-05-23 Akzo Nobel N.V. Salmonella vaccine
US7015027B1 (en) 2001-11-20 2006-03-21 Mds (Canada) Inc. Radiation therapy by accumulation of therapeutic radionuclides in tumor-targeting bacteria
JP4617449B2 (ja) 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
BR0313516A (pt) * 2002-08-16 2005-06-14 Johnson & Johnson Vision Care Moldes para a produção de lente de contato
CA2576280A1 (en) 2004-08-13 2006-02-16 Barry J. Marshall Helicobacter pylori-based delivery system
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
NZ554824A (en) 2004-10-22 2010-10-29 Revivicor Inc Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
US7766900B2 (en) 2005-02-21 2010-08-03 Biomet Manufacturing Corp. Method and apparatus for application of a fluid
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7935505B2 (en) * 2006-05-24 2011-05-03 Scarab Genomics, Llc Plasmid DNA preparations and methods for producing same
WO2008013735A2 (en) * 2006-07-21 2008-01-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8182769B2 (en) 2008-04-04 2012-05-22 Biomet Biologics, Llc Clean transportation system
US8518272B2 (en) 2008-04-04 2013-08-27 Biomet Biologics, Llc Sterile blood separating system
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
EP2348827B1 (de) 2008-10-27 2015-07-01 Revivicor, Inc. Immunsupprimierte huftiere
DK2349520T3 (en) * 2008-10-27 2016-08-15 Glaxosmithkline Biologicals Sa Purification Procedure for Group A Streptococcus Carbohydrate
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
NZ598645A (en) 2009-09-10 2014-07-25 Merial Ltd New vaccine formulations comprising saponin-containing adjuvants
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US20110201060A1 (en) * 2010-02-15 2011-08-18 Abbott Laboratories Process for the preparation of scyllo-inositol
CN103402954A (zh) 2010-10-13 2013-11-20 依兰制药公司 鲨肌醇和相关化合物的合成方法
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CN103687612B (zh) 2011-07-07 2017-12-15 由卫生福利和体育大臣代表的荷兰王国 无去污剂制备革兰氏阴性细菌外膜泡囊的方法
WO2013128288A1 (en) 2012-02-27 2013-09-06 Thelial Technologies S.A. Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics
PL2941258T3 (pl) 2013-01-02 2020-02-28 Decoy Biosystems, Inc. Kompozycje i metody leczenia nowotworów z wykorzystaniem bakterii
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US10358667B2 (en) 2013-03-07 2019-07-23 University Of Maryland, Baltimore Immunotherapeutic potential of modified lipooligosaccharides/lipid A
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10206614B2 (en) 2015-01-20 2019-02-19 Paw Bioscience Products, Llc Pre-sterilized syringe system and method of use
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3009111A1 (en) * 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Lipopolysaccharide extraction process
EP3263695A1 (de) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogene zusammensetzungen
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CA3069523A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
KR20210030973A (ko) 2018-07-11 2021-03-18 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
EP3844276A2 (de) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Manipulierte immunstimulierende bakterienstämme und verwendungen davon
CA3114110A1 (en) 2018-09-27 2020-04-02 Decoy Biosystems, Inc. Methods of treatment of infections using bacteria
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP4277654A1 (de) 2021-01-18 2023-11-22 Conserv Bioscience Limited Immunogene coronavirus-zusammensetzungen, verfahren und verwendungen davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595660A (en) * 1983-03-02 1986-06-17 University Of Delaware Molecular cloning with bifunctional plasmid vectors in Bacillus subtilis, mutants and substantially stably transformed mutants of Bacillus subtilis, and methods for utilizing the transformed mutants
US5561064A (en) * 1994-02-01 1996-10-01 Vical Incorporated Production of pharmaceutical-grade plasmid DNA
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence

Also Published As

Publication number Publication date
EP0841941A1 (de) 1998-05-20
AU2278497A (en) 1997-06-11
US6548287B1 (en) 2003-04-15
DE69635907D1 (de) 2006-05-04
US5997881A (en) 1999-12-07
EP0841941A4 (de) 2001-11-14
EP0841941B1 (de) 2006-03-08
WO1997018837A1 (en) 1997-05-29

Similar Documents

Publication Publication Date Title
ATE319476T1 (de) Neuartige nicht pyrogene bakterienstämme und ihre verwendung
HUP9900920A2 (hu) Eljárás emlőssejt-tenyészetekben termelt proteinek szializációjának szabályozására
Neeser et al. In vitro modulation of oral bacterial adhesion to saliva‐coated hydroxyapatite beads by milk casein derivatives
Huebner et al. Production of type-specific C antigen in virus-free hamster tumor cells induced by adenovirus type 12
EA200200517A1 (ru) Клеточная везикула, называемая "экзосома", ее получение и применение для стимуляции иммунного ответа
BG102130A (en) Cultivation of lawsonia intracellularis, vaccines against lawsonia intracellularis and diagnostical means
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
HUP9900768A2 (hu) Photorhabdusból származó inszekticid protein toxinok
NO20000774D0 (no) Mutanter og gram-negative mukøse bakterier, og anvendelse derav i vaksiner
DE69637942D1 (de) Stimulationsfaktor für dendriten
Peterson et al. Trichomonas vaginalis is dependent on uptake and degradation of human low density lipoproteins.
BR9811675A (pt) Genes isolados para proteìna da membrana de célula dentrìtica
DK0480949T4 (da) Fremstilling af virusvaccine
ATE159170T1 (de) Impfstoffe und diagnosetest für haemophilus influenzae
KR100366482B1 (ko) 백신으로서 정제된 분류가능하지 않은 헤모필루스 인프루엔자 p5단백질, 및 그의 정제방법
DK1192242T3 (da) Fremstilling af den lipiderede form af de peptidgylcan-associerede lipoproteiner af gramnegative bakterier
AU2002211446A1 (en) 32144, a human fatty acid amide hydrolase and uses thereof
ATE124420T1 (de) Impfstoffe und testsätze für haemophilus influenzae.
Hale et al. Antigen-liposome modification of target cells as a method to alter their susceptibility to lysis by cytotoxic T lymphocytes.
EP0689596B1 (de) Stimulierung der immunantwort durch virales protein
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
Hale et al. Elicitation of anti-viral cytotoxic T lymphocytes with purified viral and H-2 antigens.
Berthon et al. Kinetics of the in vitro antibody response to transmissible gastroenteritis (TGE) virus from pig mesenteric lymph node cells, using the ELISASPOT and ELISA tests
Warfel et al. Macrophage membrane glycoproteins that bind Griffonia simplicifolia I‐B4: Effect on cytotoxicity and protein secretion
BR9814556A (pt) Cepas isoladas de staphylococcus aureus e vacinas fabricadas a partir das mesmas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties